RecruitingAccepts healthy volunteersPhase 3

Epidemiology and Biomarker Study in Alzheimer's Disease

Eli Lilly and Company · NCT07142954

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Status re-checked against ClinicalTrials.gov within the last 12 hours.

Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts.

Participation in AACU will last approximately 7 years.

Being studied: P-tau217 Test

Conditions: Alzheimer Disease

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

The participant must self-report unimpaired cognition.
The participant must have adequate literacy, vision, and hearing for neuropsychological assessments at the time of screening.

Exclusion Criteria

Have seen a doctor about memory concerns.
Have a history or diagnosis of cognitive impairment, or significant other neurodegenerative disease that can affect cognition.
Are currently enrolled or have previously participated in any Alzheimer's Disease (AD)-related study involving an investigational drug intervention.
Are currently using or have previously used prescription medications for treatment of mild cognitive impairment (MCI) or dementia such as amyloid targeting therapy (that is, lecanemab, donanemab, aducanumab), cholinesterase inhibitors (for example, benzgalantamine, donepezil, galantamine, rivastigmine), and memantine.

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com